Scorpion Therapeutics and Pierre Fabre Laboratories Announce

Scorpion Therapeutics and Pierre Fabre Laboratories Announce First Patient Dosed in Phase 1/2 Clinical Trial of STX-721, a Mutant-Selective EGFR Exon 20 Inhibitor for the Treatment of Locally Advanced or Metastatic Non-Small Cell Lung Cancer

Scorpion Therapeutics and Pierre Fabre Laboratories Announce First Patient Dosed in Phase 1/2 Clinical Trial of STX-721, a Mutant-Selective EGFR Exon 20 Inhibitor for the Treatment of Locally Advanced or Metastatic Non-Small Cell Lung Cancer

lelezard.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from lelezard.com Daily Mail and Mail on Sunday newspapers.

Related Keywords

France , French , Axel Hoos , Michael Streit , Eric Ducournau , Pierre Fabre Laboratorie , Biomarker Research , Scorpion Therapeutics Inc , Pierre Fabre Foundation , Product Service , Locally Advanced , Metastatic Non Small Cell Lung , Precision Oncology , Pierre Fabre Laboratories , Chief Executive Officer , Pierre Fabre , Chief Medical Officer , Response Evaluation Criteria In Solid Tumors , Fabre Laboratories , Fabre Laboratorie , Non Small Cell Lung Cancer , Asian Patients ,